IQ-AI Limited (LON:IQAI) FDA Clearance to Market for StoneChecker Software

IQ-AI Announce FDA ‘Clearance to Market’ For StoneChecker Software

Imaging Biometrics, IQ-AI’s Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA.

David Smith, Chief Executive of the operating subsidiaries of IQ-AI stated, “We are delighted that after an exhaustive review of the product, that the FDA has cleared the product for marketing in the USA.”

A further announcement will be issued in the next few days, outlining the scale of the market opportunity for the product in the USA and IQ-AI’s plans for introduction.

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

stencil 20 - IQ-AI Limited (LON:IQAI) FDA Clearance to Market for StoneChecker Softwarestencil 20 - IQ-AI Limited (LON:IQAI) FDA Clearance to Market for StoneChecker Software
Share via
Copy link
Malcare WordPress Security